Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
17.15 USD -1.27% Intraday chart for Entrada Therapeutics, Inc. +21.37% +13.65%
Jun. 25 HC Wainwright Cuts Entrada Therapeutics Price Target to $18 From $20, Maintains Buy Rating MT
Jun. 24 Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Announces $100 Million Registered Direct Offering
GL
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GL
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Reports First Quarter 2024 Financial Results
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics to Present at Upcoming Investor Conferences
GL
Entrada Therapeutics Promotes Nathan J. Dowden to President
GL
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
PR
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
PR
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
GL
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
AQ
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
GL
Entrada Therapeutics to Present at Upcoming Investor Conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. News Entrada Therapeutics, Inc.
  5. Press Releases